**Low yield of unselected testing in patients with acutely abnormal liver function tests**

**Short Title: Low yield of unselected liver screens**

**Chadwick A1, Marks M1,2**

1 St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London, UK.

2 Clinical Research Department, Faculty of Infectious and Tropical Diseases, London school of Hygiene & Tropical Medicine, London, UK

**Author for correspondence:**

Michael Marks

Clinical Research Department, Faculty of Infectious and Tropical Diseases, London school of Hygiene & Tropical Medicine, London, UK

michael.marks@lshtm.ac.uk

Competing interests:

Neither author has a relevant conflict of interest.

Funding:

Michael Marks is supported by a Wellcome Trust Clinical Research Fellowship (WT102807). The funder had no role in the design, undertaking or analysis of this study.

Ethical Approval:
This was a retrospective case note review of routine clinical data meeting the NHS definition of an audit and formal institutional review board approval was therefore not required.

Guarantor:

Michael Marks is the guarantor of this article.

Contributorship:

Both authors conceived of the study, analysed the data and wrote the manuscript.

Acknowledgements:

None

**Abstract**

Objectives: To audit the diagnostic yield and cost implications of the use of a ‘liver screen’ for inpatients with abnormal liver function tests

Design: We performed a retrospective audit of inpatient with abnormal liver function tests. We analysed all investigations ordered including biochemistry, immunology, virology and radiology. The final diagnosis was ascertained in each case and the diagnostic yield and cost per positive diagnosis for each investigation were calculated.

Setting: St Thomas’ NHS Trust

Participants: All inpatients investigated for abnormal liver function tests over a twelve month period.

Main outcome Measures: We calculated the percentage of courses due to each diagnosis, the yield of each investigation and the cost per positive diagnosis for each investigation.

 Results: 308 patients were included and a final diagnosis was made in 224 patients (73%) on the basis of both clinical data and investigations . There was considerable heterogeneity in the tests included in an acute liver screen. History and ultrasound yielded the most diagnoses (40% and 30% respectively). The yield of autoimmune and metabolic screens was minimal.

Conclusions: Our results demonstrate the low yield of unselected testing in patients with abnormal liver function tests. A thorough history, ultrasound and testing for blood borne viruses are the cornerstones of diagnosis. Specialist input should be sought before further testing. Prospective studies to evaluate the yield and cost-effectiveness of different testing strategies are needed.

**Introduction**

Liver disease is increasing and now accounts for 1.5% of deaths in the United Kingdom (1). As a result the assessment of patients with both incidental and persistently abnormal liver function tests is an increasingly common clinical problem encountered by the acute physician. The use of a ‘liver-screen’ to test not only for viral causes of liver disease but also for metabolic and inherited conditions is common clinical practice (2-4) although there is limited data to support such an approach in the inpatient settings.

Studies in the community suggest that the yield of unselected testing is low. In studies of patients with incidental derangement of their liver function tests the yield of a ‘liver screen’ was between 3-10% (5,6). In contrast a cause can be identified in over 75% of patients with persistently elevated liver function tests (7-9). This suggests that biochemical liver screens can be safely delayed until a persistent elevation of liver function tests is demonstrated. The only study of acutely jaundiced patients showed imaging and clinical course to be the two most important factors in making a diagnosis (10).

Whilst individual elements of a liver screen are relatively low cost, unselected testing may result in substantial costs at a national level (11), both from direct costs associated to testing and secondly in indirect costs due to prolonged inpatient stay, without a significant improvement in diagnostic yield.

The aim of this audit was to evaluate the diagnostic yield of investigations ordered as part of routine clinical care for inpatients investigated for abnormal liver function tests at a large acute hospital.

**Methods**

Audit population:

The hospital pathology records of every patient seen between 1st January 2011 to the 31st December 2011 were reviewed. Requests for alpha-1-antitrypsin, caeruloplasmin, and liver autoantibiodies were used to identify patients undergoing an unselected liver screen. Patients were excluded they were being investigated as an outpatient or aged under 18.

Data collection

The electronic records system was used to obtain demographic data and the results of the following tests for every patient; ultrasound liver, serology for Hepatitis A, B, C, D, E, HIV, CMV and EBV, liver auto-antibodies, caeruloplasmin, alpha-1-anti-trypsin, ferritin, ANA, immunoglobulins, liver function tests and full blood count. Ultrasound reports were reviewed and patient were categorised as having evidence of steatohepatitis, cirrhosis, biliary dilatation, gallstones, gallbladder wall thickening, ascites, portal hypertension and mass lesions. The cost of investigations was provided by the hospital laboratory department. This was used to calculate the cost per positive diagnoses of each investigation.

Diagnoses

Electronic records, clinic letters and discharge letters were used to ascertain the clinical diagnosis for each patient. Where a clinical diagnosis was not given the clinical details and test results were reviewed by one author (MM) who assigned the patients to a diagnostic category.

Ethical Approval:
This was a retrospective case note review of routine clinical data meeting the NHS definition of an audit (13) and formal institutional review board approval was therefore not required.

**Results**

Three hundred and eight patients had an inpatient request for at least one of liver auto-antibodies, caeruloplasmim, alpha-1-antitrypsin in 2011. The majority were male (n = 200, 65%) with a median age of 51.5 years (IQR 41-68). Median peak ALT, ALP and Bilirubin were 76 IU/L (IQR 33-294 IU/L, normal range 3-35 IU/L), 171 IU/L (IQR 89-299 IU/L, normal range 30 to 120 IU/L) and 23 mmol/L (IQR 9-70 mmol/L, normal range 3-17 mmol/L) respectively. On review of clinical records no patient had a family history of Wilson’s disease or Alpha-1-Antitrypsin deficiency.

Testing

The frequency with which elements of the Liver Screen were sent is shown in Table 1. No investigation was organised in greater than 90% of patients. Testing for all three common hepatitis viruses (A,B,C) was carried out in 157 patients (51%). The combination of an ultrasound and testing for viral hepatitis was carried out in 110 patients (36%). Despite national guidelines (12) an HIV test was only sent in 36% of patients who had testing sent for either Hepatitis B or C. Changes consistent with steatohepatitis was the commonest finding on ultrasound (n=78, 41% of patients undergoing ultrasound, Table 2).

Diagnosis

No definitive diagnosis was made in 27% of patients despite investigation. Alcohol related liver disease (22%), malignancies (11%), viral hepatitis (10%), and gallstone disease (6%) were the commonest identified causes of abnormal liver function tests (Figure 1).

Yield and cost of diagnostic testing

Ultrasound and viral serology were the tests with the highest diagnostic yield (Table 1). Measurement of caeruloplasmin, alpha-1-antitrypsin or ferritin did not contribute to the diagnosis in any cases. The cost to yield ratio varied from £158 per positive test with ultrasound to £2,976 per positive test with liver auto-antibodies (Table 1).

**Discussion**

In this audit of investigations ordered as part of the routine clinical investigations of over 300 inpatients’ with abnormal liver function tests alcoholic liver diseases was the commonest diagnosis made. Despite extensive investigation no diagnosis was made in over a quarter of patients. History, ultrasound and testing for viral causes were the most useful elements of the diagnostic pathway. In this audit there was no diagnostic value in measuring caeruloplasmin, alpha-1-antitrypsin or ferritin. The direct cost of these tests was substantial. Although our audit does not directly address the question of delayed discharges costs it is plausible that additional testing may also contribute to indirect costs by prolonging inpatient stay.

The second major finding is the heterogeneity of the tests ordered. Only 36% of patients underwent both an ultrasound and testing for hepatitis A, B and C. Furthermore despite national guidelines for the routine testing of HIV this was undertaken in only a third of patients. These findings highlight the lack of consensus on the appropriate pathway for investigating inpatients with abnormal liver function tests. We propose that a standardised approach be taken to investigating these patients (Figure 2). Such an approach would limit unnecessary testing and ensure that patients undiagnosed after initial investigation are referred to appropriate specialists for more detailed investigations such as caeruloplasmin where appropriate.

As this was a retrospective audit of clinical practice the major limitation is that data is retrospective and partially incomplete. Patients were not systemically investigated and we cannot be certain that a final diagnosis was not missed in a number of patients. In particular it is likely that drug-induced liver function abnormalities accounted for a higher proportion of cases. Because investigations were not ordered systematically we did not perform formal statistical comparisons of the diagnostic yield of each test, although the descriptive statistics clearly highlight history, ultrasound and blood-borne virus testing as the most useful diagnostic tools. As the aim of the audit was to assess the yield of unselected testing, only patients undergoing an unselected liver screen were included, rather than all patients with bilirubineamia or transaminitis, which may have introduced a selection bias. Some patients who underwent more targeted testing, in particular for viral hepatitis, may have been excluded. Such a bias would be likely to strengthen our core results in showing that targeted with history, ultrasound and virology yield the vast majority of diagnoses whilst further decreasing the relative yield of biochemical and metabolic testing. Whilst diagnoses were assigned on the basis of combined clinical and diagnostic data, ultrasound findings such as steatohepatitis can be non-specific. It is possible that some cases classified as alcoholic hepatitis on the basis of an appropriate clinical history and ultrasound findings may in fact have been due to other undiagnosed causes. Finally this audit only included inpatients with abnormal liver function tests. As such the findings may not be generalisable to primary care or outpatient settings where a different diagnostic pathway may be appropriate.

Despite these limitations this audit includes a large number of both surgical and medical inpatients with abnormal liver function tests and is likely to reflect everyday clinical practice. The findings of our audit are in agreement with a previous study in Denmark (10), which showed history and imaging to be most useful when investigating hyperbilirubinaemia. The percentage of patients in whom no diagnosis was made is also similar to previous studies. Clinical evaluation and directed testing diagnose nearly all patients with an identifiable cause for their abnormal LFTs. Our findings suggest that the routine use of unselected testing in patients with abnormal liver function tests is both clinically unjustified and is likely to result in significant unnecessary expenditure on both direct and indirect costs. Approaches to decrease unselected testing such as informing clinicians of the cost of tests (14) should be considered.

In conclusion our audit demonstrates there is a considerable heterogeneity in the evaluation of inpatients with abnormal liver function tests and that a number of commonly requested tests have minimal yield in the routine inpatient setting but result in substantial expenditure. Our audit highlights the need for a prospective evaluation of the yield and cost-effectiveness of different testing strategies to enable the development of a standardised approach to the investigation of inpatients with abnormal liver function tests. Such an approach would be likely to improve both clinical and financial outcomes.

References:

1) British Society of Gastroenterology. Commissioning report on Jaundice and Abnormal Liver Function Tests. Available at <http://www.bsg.org.uk/images/Commissioning_report/BSG_Jaundice_and_Abnormal_Liver_Function_Tests.pdf> [Accessed 07/05/2013]

2) British Society of Gastroenterology. Management of Abnormal LFT in Asymptomatic Patients. Available at: <http://www.bsg.org.uk/pdf_word_docs/ablft_draft05.doc> [Accessed 07/05/13]

3 - Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. *Postgrad Med J* 2003;79:307–312

4 - Daniel S. Pratt, M.D., and Marshall M. Kaplan, M.D. Evaluation of Abnormal Liver-Enzyme Results in Asymptomatic Patients. N Engl J Med 2000; 342:1266-1271April 27, 2000

5 – Armstrong MJ, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. Journal of hepatology. J Hepatol. 2012 Jan;56(1):234-40

6 - Kundrotas LW, Clement DJ. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci. 1993;38(12):2145.

7 - Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol. 1999;94(10):3010.

8 - Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol. 1986;21(1):109.

9 - Mathiesen UL, Franzén LE, Frydén A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol. 1999 Jan;34(1):85-91.

10 - Reisman Y, Gips CH, Lavelle SM, Wilson JH. Clinical presentation of (subclinical) jaundice--the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology. 1996 Sep-Oct;43(11):1190-5.

11 – Marks M. Routine test batteries for cognitive impairment in older people may not be cost effective. [http://www.ncbi.nlm.nih.gov/pubmed/21971166 - #](http://www.ncbi.nlm.nih.gov/pubmed/21971166##)BMJ 2011 Oct 4;343:d6330. doi: 10.1136/bmj.d6330.

12 – British HIV Association. UK National Guidelines for HIV Testing. 2008. Available at <http://www.bhiva.org/documents/Guidelines/Testing/GlinesHIVTest08.pdf> [Accessed 07/05/2013]

13 – NHS Health Research Authority. Determine whether your study is research. Available at

http://www.hra.nhs.uk/research-community/before-you-apply/determine-whether-your-study-is-research

14 – Feldman LS, et al. Impact of Providing Fee Data on Laboratory Test Ordering – A Controlled Clinical Trial. JAMA Intern Med. 2013 doi:10.1001/jamainternmed.2013.232

Figure 1: Diagnosis for abnormal liver function tests

Alcoholic liver disease and biliary disease were the major causes of abnormal liver function tests. The yield of autoimmune and metabolic testing was minimal.

Figure 2: Approach to investigating abnormal liver function tests in in-patients

A detailed history and review of medications is key to establishing the underlying diagnosis. Initial diagnostic testing should be limited to imaging and blood borne virus testing.

Table 1: Tests requested in investigation of abnormal liver function tests

|  |  |  |  |
| --- | --- | --- | --- |
| TEST | Number (%) Test Performed | Number (%) Diagnosis Reached\* | Cost per Diagnosis |
| History | N/A | 90 (40%) | N/A |
| Ultrasound | 189 (69%) | 67 (30%) | £158 |
| Hepatitis A | 168 (55%) | 6 (3%) | £857 |
| Hepatitis B | 238 (77%) | 9 (4%) | £1,044 |
| Hepatitis C | 233 (76%) | 15 (7%) | £265 |
| Autoimmune (all) | 269 (87%) | 3 (1%) | £2,796 |
| Metabolic Tests (any) | 145 (47%) | 0 (0) | # |

\*This shows the percentage of diagnosis’ reached due predominantly to the test in cases where a diagnosis was reached n = 224

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

90 (40.2)

N/a

History

67 (30)

189 (61%)

Ultrasound

0 (0)

145 (47%)

Metabolic Tests (any)

269 (87%)

233 (76%)

238 (77%)

**Number (%) Test Performed**

**Test**

**Number (%) diagnosis made\***

Hepatitis B screen

9 (4)

Hepatitis C screen

15 (6.7)

Autoimmune screen

3 (1.3)

# No diagnoses were made via metabolic testing therefore a cost per diagnosis can not be calculated. Sending Alpha-1-Antitrypsin, Caeruloplasmin and Ferritin as screening tests costs £18.42 per patient.

Table 2: Findings on Ultrasound:

|  |  |
| --- | --- |
| Finding | Frequency |
| Steatohepatitis | 41% |
| Splenomegaly | 20% |
| Ascites | 20% |
| Hepatomegaly | 16% |
| Gallbladder / Biliary Tract Disease | 16% |
| Cirrhosis | 13% |
| Liver Mass | 5% |
| Pancreatic Abnormality | 4% |

189 Patients underwent ultrasound